Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited ( (AU:BDX) ) has issued an update.
BCAL Diagnostics has reported a change in the interests of director Jayne Shaw, who has both direct and indirect holdings in the company’s securities. Through entities she controls and in her own name, Shaw maintains substantial share and option positions, underscoring her significant financial exposure to the company’s performance.
The latest filing shows Shaw acquired 85,000 ordinary shares via an on-market purchase for about $8,477, with no disposals recorded. The transaction did not occur during a closed trading period, and her updated holdings reflect continued confidence and alignment with shareholder interests.
The most recent analyst rating on (AU:BDX) stock is a Sell with a A$0.09 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited operates in the medical diagnostics sector, focusing on the development of diagnostic technologies and products. The company is listed on the ASX and its securities are actively traded, with directors and associated entities holding significant share and option positions.
Average Trading Volume: 286,461
Technical Sentiment Signal: Sell
Current Market Cap: A$35.39M
See more data about BDX stock on TipRanks’ Stock Analysis page.